Can You Die From Polymyalgia Rheumatica?

Polymyalgia rheumatica itself does not appear to shorten your life. Multiple population-based studies spanning decades have found that people diagnosed with isolated PMR die at roughly the same rate as everyone else their age. But the full picture is more layered than that reassuring headline, because PMR overlaps with a more dangerous condition called giant cell arteritis, and the long-term steroid treatment PMR requires carries its own serious risks.

What the Mortality Data Actually Show

The most comprehensive evidence comes from a 38-year population-based study in southern Norway that tracked every diagnosed PMR case in the region. For patients with isolated PMR (meaning no concurrent giant cell arteritis), overall survival was statistically indistinguishable from matched controls in the general population. The standardized mortality ratio was 0.97, meaning PMR patients died at a rate almost identical to what would be expected for people of the same age and sex without the disease.¹ A large retrospective study confirmed this, finding an adjusted mortality rate ratio of 1.00 when comparing PMR patients to matched controls.²

One earlier prospective study of 315 cases actually found that PMR patients died at a lower rate than controls, with about 21% of patients dying during follow-up compared to about 27% of matched population controls.³ That finding likely reflects a detection bias: people who get diagnosed with PMR are already in regular medical care, and their other health problems get caught earlier. The honest takeaway across all these studies is that PMR by itself does not raise your risk of dying. What can be dangerous, though, is what sometimes accompanies it.

The Giant Cell Arteritis Connection

Giant cell arteritis, or GCA, is an inflammatory condition that targets medium and large arteries, especially those around the temples and the aorta. PMR and GCA are closely related. A meta-analysis estimated that about 22% of people diagnosed with PMR also have GCA present at the time of diagnosis, though individual study estimates ranged widely from 6% to 66% depending on how hard clinicians looked for it.⁴ Other estimates place the overlap between 16% and 21%.⁵

GCA matters because it can cause vascular complications that PMR alone does not. In the Norwegian cohort study, the patients who did have elevated mortality were those with concurrent GCA, not those with PMR alone.¹ If you have PMR and start experiencing new headaches, jaw pain while chewing, visual changes, or scalp tenderness, those are warning signs of GCA that warrant urgent evaluation. Untreated GCA can lead to permanent vision loss or, more rarely, the vascular emergencies described below.

Aortic Aneurysm and Dissection in GCA

The most life-threatening complication of GCA is large-artery involvement, particularly thoracic aortic aneurysm and dissection. A population-based study found that patients with GCA were over 17 times more likely to develop a thoracic aortic aneurysm than people of the same age and sex without the disease. Six of the 11 patients who developed thoracic aneurysms died suddenly from acute aortic dissection.⁶ Among GCA patients who developed thoracic aortic dissection, median survival was only about one year.⁷

A more recent 70-year population study found that GCA patients with any large-artery involvement had almost double the risk of death compared to GCA patients without it. The risk was highest for those who developed aortic dissection specifically, with an over 11-fold increased risk of death compared to those with other forms of large-artery disease.⁸ The cumulative incidence of aortic aneurysm or dissection at 15 years reached roughly 19-21% in some time intervals of that study, which is a sobering number for patients whose PMR turns out to have GCA hiding behind it.

This is why the distinction between “isolated PMR” and “PMR with underlying GCA” matters so much for the mortality question. PMR alone does not kill. GCA with large-artery involvement can.

Cardiovascular Risk Beyond GCA

Given that PMR is an inflammatory disease affecting older adults, you might assume it raises the risk of heart attacks and strokes. The evidence here is surprisingly reassuring for isolated PMR. A large study of cardiovascular outcomes found that patients with PMR and/or GCA actually had a slightly lower incidence of fatal and non-fatal cardiovascular disease than those without, with lower rates of sudden coronary death and transient ischemic attacks.⁹ That counterintuitive finding may again reflect closer medical monitoring and more aggressive management of risk factors in patients already under rheumatology care.

The picture is different for blood clots. A study in the Veterans Health Administration found that patients with GCA had a higher risk of deep vein thrombosis, pulmonary embolism, and retinal vascular occlusions compared to those with PMR alone or osteoarthritis controls. GCA patients were roughly twice as likely to develop deep vein thrombosis compared to those with overlapping PMR/GCA, and nearly five times more likely to have retinal vascular occlusions compared to patients with PMR alone.¹⁰ Again, the risk concentrates in GCA rather than isolated PMR.

The Steroid Problem

Here is where PMR does create genuine danger, even without GCA. The standard treatment for PMR is glucocorticoid therapy, typically prednisone, often for one to three years and sometimes longer. Steroids work well for symptom control, but the cumulative side effects of long-term use create their own health burden. Whether PMR itself raises these risks or the steroids do is a question researchers have wrestled with, and the honest answer is that disentangling the two is nearly impossible because virtually every PMR patient receives glucocorticoids.

One population-based study found that the risk of fracture was increased by about 63% in PMR patients compared to the general population, yet fewer than 13% of those on glucocorticoids were prescribed bone-protecting medications.¹¹ An earlier study found that the risks of diabetes, vertebral fractures, femoral neck fractures, and hip fractures were two to five times greater in PMR patients compared to matched individuals.¹² A retrospective Italian study found that longer duration of glucocorticoid treatment and higher cumulative doses were significantly associated with osteoporosis, fragility fractures, high blood pressure, and heart attacks.¹³

Not every study agrees on the magnitude. A Mayo Clinic cohort study found comparable rates of diabetes, hypertension, high cholesterol, and fractures between PMR patients and matched comparators, suggesting that at least some of these risks may reflect the age group PMR affects rather than the treatment itself.¹⁴ That study stands somewhat apart from the broader literature, though, and its findings may reflect differences in prescribing practices or how carefully bone-protective therapy was used. For individual patients, especially those who end up on steroids for years rather than months, the fracture and infection risk is real and worth discussing with a doctor.

Infections and Hospitalization

Glucocorticoids suppress the immune system, and that immunosuppression exposes PMR patients to serious infections. A national U.S. study found that sepsis rates among hospitalized PMR patients reached about 18% in recent years, substantially higher than the roughly 10% rate in the general population. Sepsis had overtaken pneumonia as the most common serious infection in PMR patients by 2011-2012, and among PMR patients, sepsis along with higher comorbidity burden and certain hospital characteristics were associated with higher in-hospital mortality.¹⁵ Hip fractures in older adults can also be fatal: a broken hip in someone over 70 carries substantial mortality within the following year, and the elevated fracture risk from steroids feeds directly into that.

A PMR cohort study found that about 17% of participants reported a fragility fracture at baseline, and a history of falls was the strongest predictor of fracture at both 12 and 24 months of follow-up.¹⁶ Falls, fragility, steroids, and advanced age create a compounding risk that, while not directly caused by PMR itself, is a direct consequence of living with and being treated for the disease.

Relapses and Prolonged Treatment

One reason steroid side effects accumulate is that PMR is difficult to shake. A meta-analysis found that about 43% of patients experienced at least one relapse within the first year of treatment, and across individual studies, the proportion of patients relapsing at some point during follow-up ranged from 22% to 67%.¹⁷ A Japanese cohort reported five-year relapse-free survival of only about 52%, and among patients who relapsed once, the three-year rate of a second relapse was over 70%.¹⁸

Each relapse typically means bumping the steroid dose back up and restarting the taper, which extends total treatment duration and adds to the cumulative dose your body absorbs. Research has found that persistently elevated inflammatory markers during the first year of treatment are associated with a higher risk of relapse, suggesting that some patients have a more stubborn inflammatory process that resists the standard approach.¹⁹ Elevated levels of a specific inflammatory signaling molecule at baseline, combined with low hemoglobin, carried roughly a tenfold increased risk of relapse in one study.²⁰ This is relevant to the mortality question because it means a substantial minority of patients cannot simply take steroids for a year and stop. They end up on glucocorticoids for much longer, absorbing more cumulative harm.

Steroid-Sparing Treatment Options

The recognition that long-term glucocorticoids are the main source of harm in PMR has driven interest in drugs that might let patients taper off steroids faster. Tocilizumab, an anti-inflammatory biologic that blocks a key inflammatory signaling pathway, has shown promise. In a randomized trial, about 63% of PMR patients on tocilizumab achieved glucocorticoid-free remission by week 16 compared to roughly 12% on placebo.²¹ A larger randomized trial found that by week 24, about half of patients receiving tocilizumab were off glucocorticoids entirely, compared to about 20% on placebo.²²

A systematic review and meta-analysis confirmed that tocilizumab significantly lowered the total amount of glucocorticoids patients needed.²³ While tocilizumab has its own side effects, reducing cumulative steroid exposure is potentially significant for long-term outcomes. This is still a relatively new approach, and not every patient with PMR will need or be offered biologic therapy, but it represents a meaningful shift in how the disease can be managed.

When PMR Is Not Really PMR

A different kind of danger arises when something that looks like PMR turns out to be something else entirely. Several conditions mimic PMR’s hallmark symptoms of bilateral shoulder and hip stiffness with elevated inflammatory markers. Elderly-onset rheumatoid arthritis is one of the most common mimics, and distinguishing the two early on can be genuinely difficult because both cause morning stiffness and joint pain in the same age group.²⁴ Misdiagnosing rheumatoid arthritis as PMR can delay appropriate disease-modifying treatment and lead to joint damage.

More ominously, PMR symptoms sometimes appear as a paraneoplastic syndrome, meaning the body’s response to an underlying cancer mimics PMR. These cases tend to present atypically and respond poorly to standard glucocorticoid doses.²⁵ If you have been diagnosed with PMR but your symptoms do not improve substantially with steroids within the first week or two, that poor response itself is a red flag that warrants further investigation. A cancer masquerading as PMR is rare, but it is one of the situations where the question “can PMR kill you” takes on a different and more urgent meaning.

Mental Health and Glucocorticoid Side Effects

The toll of PMR extends beyond physical complications. Depression rates among PMR patients are markedly higher than in the general population. One study found that about 22-25% of PMR patients met criteria for depression at diagnosis, compared to 0-3% of age-matched controls. Depression was strongly linked to current steroid dose, disease activity, pain, and fatigue.²⁶

Glucocorticoids themselves can cause psychiatric side effects that go well beyond mood changes. A large primary-care study found that compared to people with the same underlying diseases who were not treated with glucocorticoids, steroid-treated patients had a nearly sevenfold higher risk of suicide or suicide attempt, a roughly fourfold higher risk of mania, and a fivefold higher risk of delirium or confusion.²⁷ These are not common outcomes, and the doses used for PMR are lower than those used for many other conditions, but the risk is not trivial and is something patients and their families should be aware of, especially during the early weeks of treatment or after dose increases.

Frailty, Falls, and Functional Decline

PMR affects people over 50, with the average age at diagnosis typically in the early-to-mid 70s. In this age group, the combination of painful stiffness, reduced physical activity, steroid-induced muscle weakness, and bone thinning can tip someone from independence into frailty. Frailty in this context means a reduced ability to bounce back from even minor physical stresses, like a fall or a chest infection, which increases the risk of hospitalization, loss of independence, and death.²⁸

There are no PMR-specific guidelines for managing frailty, but general principles apply: staying as physically active as the disease allows, maintaining adequate protein intake to limit muscle loss, ensuring bone-protective medication is prescribed when steroids are used long term, and addressing fall risk factors like poor balance or home hazards. These practical steps won’t cure PMR, but they can meaningfully reduce the indirect harms that accumulate around it. The disease itself may not shorten your life, but the cascade of inactivity, steroid side effects, and age-related vulnerability can erode quality of life in ways that eventually affect survival if left unaddressed.